IPO « Science and Enterprise

Cancer T-Cell Start-Up Gains $150 Million in IPO

By Alan, on June 25th, 2018%

A three year-old company developing treatments for cancer with engineered T-cells from the immune system raised $150 million in its initial public offering of common stock. . . . → Read More: Cancer T-Cell Start-Up Gains $150 Million in IPO

Multi-Drug Resistance Antibiotic Developer to Issue IPO

By Alan, on October 24th, 2017%

A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering. . . . → Read More: Multi-Drug Resistance Antibiotic Developer to Issue IPO

Cancer Gene Therapy Company Raises $85M in IPO

By Alan, on April 13th, 2017%

A developer of cancer immunotherapies that transfer gene treatments into patients with brain tumors is raising $85 million in its initial public stock offering. . . . → Read More: Cancer Gene Therapy Company Raises $85M in IPO

Medical Robotics Company Crowdfunding IPO

By Alan, on March 15th, 2017%

A medical robotics company spun-off from labs at MIT is issuing its initial public stock offering through equity crowdfunding, aiming to raise $15 million. . . . → Read More: Medical Robotics Company Crowdfunding IPO

Immunotherapy Biotech Raises $102 Million in IPO

By Alan, on January 27th, 2017%

A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering. . . . → Read More: Immunotherapy Biotech Raises $102 Million in IPO

Biopharm Company Raising $40 Million in IPO

By Alan, on August 11th, 2016%

Omeros Corporation, a biopharmaceutical company developing drugs that prevent inflammation in surgeries, is raising $40 million in its initial public stock offering. . . . → Read More: Biopharm Company Raising $40 Million in IPO

Immunotherapy Company Raises $70 Million in IPO

By Alan, on June 22nd, 2016%

Selecta Biosciences, a biotechnology company developing treatments harnessing the immune system, is raising $70 million in its initial public offering. . . . → Read More: Immunotherapy Company Raises $70 Million in IPO

Genome-Editing Company Raises $108 Million in IPO

By Alan, on May 6th, 2016%

Artist depiction of Cas9 protein editing a gene (Jennifer Doudna, University of California – Berkeley)

6 May 2016. Intellia Therapeutics, a developer of therapies based on genome editing, issued its initial public stock offering, raising $108 million. The Cambridge, Massachusetts enterprise, less than 2 years old, issued 6 million shares priced at $18.00. . . . → Read More: Genome-Editing Company Raises $108 Million in IPO

Cancer Diagnostics Company Raises $12.3M in IPO

By Alan, on March 18th, 2016%

(A. Kotok)

18 March 2016. VolitionRx, a developer of blood tests that screen for cancer and other disorders, is raising some $12.3 million in its initial public stock offering. The Namur, Belgium company, listed on the New York Stock Exchange under the symbol VNRX, issued about 3.8 million shares of common stock priced . . . → Read More: Cancer Diagnostics Company Raises $12.3M in IPO

Genome-Editing Company Raises $94 Million in IPO

By Alan, on February 3rd, 2016%

(bfishadow, WikimediaCommons)

3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 . . . → Read More: Genome-Editing Company Raises $94 Million in IPO

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise